Literature DB >> 20558728

Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.

Sanchari Bhattacharyya1, Roshan Elizabeth Rajan, Yalla Swarupa, Ujjwal Rathore, Anjali Verma, Ranga Udaykumar, Raghavan Varadarajan.   

Abstract

The outer domain (OD) of the HIV-1 envelope glycoprotein gp120 is an important target for vaccine design as it contains a number of conserved epitopes, including a large fraction of the CD4 binding site. Attempts to design OD-based immunogens in the past have met with little success. We report the design and characterization of an Escherichia coli-expressed OD-based immunogen (OD(EC)), based on the sequence of the HxBc2 strain. The OD(EC)-designed immunogen lacks the variable loops V1V2 and V3 and incorporates 11 designed mutations at the interface of the inner and the outer domains of gp120. Biophysical studies showed that OD(EC) is folded and protease-resistant, whereas OD(EC) lacking the designed mutations is highly aggregation-prone. In contrast to previously characterized OD constructs, OD(EC) bound CD4 and the broadly neutralizing antibody b12 but not the non-neutralizing antibodies b6 and F105. Upon immunization in rabbits, OD(EC) was highly immunogenic, and the sera showed measurable neutralization for four subtype B and one subtype C virus including two b12-resistant viruses. In contrast, sera from rabbits immunized with gp120 did not neutralize any of the viruses. OD(EC) is the first example of a gp120 fragment-based immunogen that yields significant neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558728      PMCID: PMC2930709          DOI: 10.1074/jbc.M110.152272

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Authors:  Peter D Kwong; Michael L Doyle; David J Casper; Claudia Cicala; Stephanie A Leavitt; Shahzad Majeed; Tavis D Steenbeke; Miro Venturi; Irwin Chaiken; Michael Fung; Hermann Katinger; Paul W I H Parren; James Robinson; Donald Van Ryk; Liping Wang; Dennis R Burton; Ernesto Freire; Richard Wyatt; Joseph Sodroski; Wayne A Hendrickson; James Arthos
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  Design of a novel globular protein fold with atomic-level accuracy.

Authors:  Brian Kuhlman; Gautam Dantas; Gregory C Ireton; Gabriele Varani; Barry L Stoddard; David Baker
Journal:  Science       Date:  2003-11-21       Impact factor: 47.728

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescent probe of non-polar binding sites.

Authors:  L Stryer
Journal:  J Mol Biol       Date:  1965-09       Impact factor: 5.469

5.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.

Authors:  E Helseth; U Olshevsky; C Furman; J Sodroski
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope.

Authors:  Laurent Dacheux; Alain Moreau; Yasemin Ataman-Onal; François Biron; Bernard Verrier; Francis Barin
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.

Authors:  C F Barbas; E Björling; F Chiodi; N Dunlop; D Cababa; T M Jones; S L Zebedee; M A Persson; P L Nara; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

8.  Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding.

Authors:  Y Li; L Luo; N Rasool; C Y Kang
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

9.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Authors:  Kaustuv Banerjee; Sofija Andjelic; Per Johan Klasse; Yun Kang; Rogier W Sanders; Elizabeth Michael; Robert J Durso; Thomas J Ketas; William C Olson; John P Moore
Journal:  Virology       Date:  2009-05-02       Impact factor: 3.616

10.  Effect of signal peptide on the stability and folding kinetics of maltose binding protein.

Authors:  K Beena; Jayant B Udgaonkar; R Varadarajan
Journal:  Biochemistry       Date:  2004-03-30       Impact factor: 3.162

View more
  20 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Stalking influenza.

Authors:  Debra M Eckert; Michael S Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

3.  Existence of different structural intermediates and aggregates on the folding pathway of ovalbumin.

Authors:  Afshin Iram; Aabgeena Naeem
Journal:  J Fluoresc       Date:  2011-08-12       Impact factor: 2.217

4.  Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.

Authors:  Ujjwal Rathore; Piyali Saha; Sannula Kesavardhana; Aditya Arun Kumar; Rohini Datta; Sivasankar Devanarayanan; Raksha Das; John R Mascola; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

5.  Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.

Authors:  Sanchari Bhattacharyya; Pranveer Singh; Ujjwal Rathore; Mansi Purwar; Denise Wagner; Heather Arendt; Joanne DeStefano; Celia C LaBranche; David C Montefiori; Sanjay Phogat; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

Review 6.  Advances in structure-based vaccine design.

Authors:  Daniel W Kulp; William R Schief
Journal:  Curr Opin Virol       Date:  2013-06-25       Impact factor: 7.090

7.  Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.

Authors:  Yali Qin; Marisa Banasik; SoonJeung Kim; Adam Penn-Nicholson; Habtom H Habte; Celia LaBranche; David C Montefiori; Chong Wang; Michael W Cho
Journal:  Virology       Date:  2014-08       Impact factor: 3.616

8.  Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.

Authors:  Ujjwal Rathore; Mansi Purwar; Venkada Subramanian Vignesh; Raksha Das; Aditya Arun Kumar; Sanchari Bhattacharyya; Heather Arendt; Joanne DeStefano; Aaron Wilson; Christopher Parks; Celia C La Branche; David C Montefiori; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

9.  Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.

Authors:  Sannula Kesavardhana; Raksha Das; Michael Citron; Rohini Datta; Linda Ecto; Nonavinakere Seetharam Srilatha; Daniel DiStefano; Ryan Swoyer; Joseph G Joyce; Somnath Dutta; Celia C LaBranche; David C Montefiori; Jessica A Flynn; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2016-11-22       Impact factor: 5.157

Review 10.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.